US court rejects Teva’s patent-infringement claims on Copaxone
Mylan NV has been trying to market a generic version of Teva Pharma’ Copaxonee drug used for the treatment of multiple sclerosis
Latest News »
- Cyberattack hits UK Parliament, limiting access to MPs’ emails
- Narendra Modi will convey Indian IT firms’ role in US to Trump: Vishal Sikka
- Gujarat Congress leader Shankarsinh Vaghela hits out at party leadership
- Yogi Adityanath govt launches ‘informer scheme’ to curb female foeticide
- World Taekwondo Federation changes its name over ‘negative’ acronym
Bengaluru: Teva Pharmaceutical Industries Ltd said on Monday a US court rejected four of the Israel-based drugmaker’s claims of patent infringement on its top-selling multiple sclerosis treatment.
The rejection comes four months after US patent officials invalidated three patents on its drug Copaxone, in response to challenges by pharmaceutical company Mylan NV, which has been trying to market a generic version of the drug.
All asserted claims of Teva were invalid, the US District Court Of Delaware said in a ruling on Monday.
The patents, which expire in 2030, cover a 40-milligram injection of Copaxone that patients administer three times a week.
Generics may only be sold after a drug’s patents expire or are invalidated through litigation.
However, Teva said it planned to appeal the decision.
US-listed shares of Teva were down almost 9% in after-hours trading, while Mylan’s shares edged up marginally. Reuters